Developer docs
API playgroundTry for free, no card

Search company profiles

Molecular Health

Full company profile

uuid0006e5d

Namestring
Molecular Health
Legal namestring
Molecular Health GmbH
Company typeenum
Private
Founded yearint
2014
Descriptiontext

Molecular Health GmbH, founded in 2014 and headquartered in Heidelberg, Germany with a wholly-owned U.S. subsidiary (Molecular Health Inc.), develops AI-driven biomedical data intelligence software for pharmaceutical, biotechnology, and research laboratory customers. Its core technology platform, Dataome Technology, uses proprietary AI/ML text-mining combined with expert curation to structure and integrate molecular, biomedical, and drug-related data into a proprietary knowledgebase covering the human molecular landscape. On top of this platform the company offers two product lines: MH Guide / MH Guide CAS, variant annotation and reporting software for genetic and molecular tumor data (with sub-modules including MH Guide/BRCA for PARP inhibitor variant interpretation and MH Guide/Mendel for hereditary disease genes); and AI Pharma Solutions, a fee-for-service offering for indication finding, biomarker discovery, target identification, trial design and endpoint optimization, and drug safety prediction via the MH Effect and MH Predict technologies.

The company operates an enterprise field sales motion targeting pharma/biotech and research laboratories, with dedicated customer success teams in Germany and the U.S. and contact-based pricing (no published tiers). Distribution is augmented by strategic channel partnerships, notably a global multi-year agreement with Integrated DNA Technologies (IDT, May 2024) pairing MH Guide with IDT's Archer NGS assay platform, and a strategic collaboration with Axxam S.p.A. (June 2025) pairing Dataome insights with biological validation for drug target discovery. Molecular Health is privately held by its founders (CEO Dr. Friedrich von Bohlen und Halbach; CTO Dr. Stephan Brock) with no disclosed external funding rounds or parent company, operates under GDPR-compliant data practices, and maintains an active scientific publication record (18 articles spanning 2016-2026).

Short descriptiontext

Molecular Health is a Heidelberg-based AI biomedical data intelligence company that operates the Dataome knowledge platform and MH Guide variant annotation software to serve pharmaceutical, biotech, and research laboratory customers with drug development and clinical genomics analytics.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
101–250
akta.pro rankint
HeadquartersHeidelberg, Germany
HQ citystring
Heidelberg
HQ countrystring
Germany
HQ regionstring
Europe
Markets served

Serves global market

Offices4 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
biomedical data analytics, variant annotation software, AI drug discovery, clinical genomics software, biomedical knowledge platform
Industry3 codes
PRIMARYHLAGAJAO
AI/ML Platforms for Drug Discovery & Experiment Optimization
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Life Science Software & Informatics (LIMS/ELN/Bioinformatics)
SECONDARYHLAAAIAI
Target Identification & Validation Platforms (omics-driven, chemoproteomics, genetic validation)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAAALAO
Digital & AI-Enabled Diagnostics (algorithmic interpretation, decision support tied to assays)
NAICS code2 codes
  • Software Publishers5132
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
Product category
Clinical Genomics and Bioinformatics Software
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model3 records
1Software Solutions for Research
TypeSubscription Recurring
Description

Software licensing and subscription services for variant annotation, reporting, and analysis tools used by research laboratories and pharmaceutical companies. Includes MH Guide CAS for genetic data annotation.

molecularhealth.com
2AI Pharma Solutions Services
TypeProfessional Services
Description

Fee-for-service analytical projects using Dataome Technology for indication finding, biomarker discovery, target identification, trial design, endpoint optimization, and safety prediction.

molecularhealth.com
3Integrated Software Partnerships
TypeLicensing Royalties
Description

Revenue through partnership arrangements that integrate Molecular Health's software with partner platforms (e.g., IDT's NGS workflow), extending distribution reach.

molecularhealth.com
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Personnel, Operations, Marketing or Sales, Others
GTM typeB2B
B2B
Offering typeSoftware
Software
Brand1 of 3 records shown
1MH Guide CAS
Description

Case Annotation Solution for annotating genetic and molecular tumor alteration data with published therapy associations, biomarkers, and recruiting clinical trials for research guidance.

molecularhealth.com
+2 more records
Core offering1 text field

Molecular Health develops and sells AI-powered software that transforms biomedical and molecular data into actionable insights for drug development and clinical genomics. Its primary products are MH Guide (a variant annotation and clinical reporting software for genetic and tumor data) and the Dataome biomedical knowledge base, complemented by AI Pharma Solutions services that apply these capabilities to indication finding, biomarker discovery, target identification, trial design optimization, and drug safety prediction for pharmaceutical and research laboratory customers.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 value
  • Provides tertiary analysis for NGS data, maximizing lab efficiency and streamlining genomics workflows
Product overview1 text field

Molecular Health offers a platform-plus-modules architecture centered on Dataome Technology and MH Guide. Dataome is the core AI-powered biomedical knowledge base that integrates and contextualizes molecular, biomedical, and drug-related data. MH Guide is the primary clinical software for annotating genetic variants with therapy associations and biomarkers. These are supplemented by specialized modules including MH Guide/BRCA for BRCA variant interpretation, MH Guide/Mendel for hereditary disease genes, MH Order Portal for case management, and MH VCF Adapter Suite and MH Connector for NGS workflow integration. The AI Pharma Solutions product line leverages Dataome for pharma/biotech clients requiring indication finding, biomarker identification, target identification, trial design optimization, and drug safety prediction via MH Effect technology.

Product and service1 record
1MH Guide / MH Guide CAS (Case Annotation Solution)
Scale indicator3 records

Each record includes

Type, Value, Description, Source

Partnership2 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-06-04
Description

Strategic collaboration pairing data-driven clinical-molecular insights with biological validation to identify relevant drug targets and confirm leads for biopharmaceutical companies. Combines Molecular Health's Dataome Technology with Axxam's integrated early discovery services capabilities.

Strategic tierCoreTypeChannel Partner/ Reseller/ DistributorAnnounced on2024-05-15
Description

Global multi-year agreement pairing IDT's Archer NGS research assay platform with Molecular Health's variant annotation and reporting software. Equips molecular researchers with tertiary analysis for NGS data, maximizing lab efficiency and streamlining genomics data workflows. Extends access to research customers through IDT's nationwide (U.S.) footprint and global presence. Collaboration enables high-quality, end-to-end integration plus deep understanding of sequencing data for cancer discoveries.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

SOPHiA Genetics provides AI-powered variant annotation and interpretation for clinical and research genomics. Both companies offer tertiary NGS analysis, biomarker annotation, and clinical trial matching for pharma/research customers, directly competing in variant interpretation.

TypeDirect peer
Description

Fabric Genomics specializes in NGS variant interpretation and clinical decision support for genomic medicine. Directly comparable to Molecular Health's MH Guide and MH Guide CAS for variant annotation, reporting, and clinical research workflows.

TypeDirect peer
Description

Congenica provides clinical genomics interpretation software for rare disease and hereditary cancer variants. Comparable use cases to Molecular Health's MH Guide/Mendel and MH Guide/BRCA modules for hereditary disease gene interpretation.

TypeDirect peer
Description

Golden Helix offers variant annotation and clinical reporting software for NGS workflows. Competes in similar territory as Molecular Health's MH Guide CAS for research laboratories and clinical genomics reporting.

TypeBroad incumbent
Description

QIAGEN is a major life sciences tools and bioinformatics provider offering QIAseq and Ingenuity variant analysis tools. Broader portfolio than Molecular Health but significant overlap in NGS variant interpretation and clinical genomics workflows.

TypeDirect peer
Description

Schrödinger provides a computational platform for drug discovery including target identification, molecular design, and predictive modeling. Comparable to Molecular Health's AI Pharma Solutions and Dataome Technology for pharma/biotech target identification and indication finding.

TypeDirect peer
Description

Recursion is an AI-driven drug discovery platform combining high-throughput biology with machine learning. Overlaps with Molecular Health's AI Pharma Solutions for target identification, indication finding, and predictive analytics in pharma/biotech.

TypeDirect peer
Description

Exscientia applies AI to drug design and target discovery with patient-derived data. Comparable to Molecular Health's predictive analytics capabilities for drug development, indication finding, and safety prediction.

9Tempus AI
TypeBroad incumbent
Description

Tempus AI is a data-driven precision medicine company offering AI-enabled diagnostics, biomarker discovery, and clinical trial matching. Broader portfolio but overlapping use cases in biomarker identification, trial matching, and pharma data services.

TypeBroad incumbent
Description

Illumina is the dominant NGS platform provider with adjacent bioinformatics offerings through BaseSpace and various partnerships. As a broader incumbent, Illumina's ecosystem competes with Molecular Health's IDT partnership for NGS workflow ownership.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers2 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

Integration2 records

Each record includes

Title, Type, Description, Source

AI capability6 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature6 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles4 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries1 record

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

Compliance1 record

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds1 record

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors1 record

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Molecular Health

Clinical Genomics and Bioinformatics Softwaremolecularhealth.com

Molecular Health is a Heidelberg-based AI biomedical data intelligence company that operates the Dataome knowledge platform and MH Guide variant annotation software to serve pharmaceutical, biotech, and research laboratory customers with drug development and clinical genomics analytics.

What Molecular Health does

Molecular Health GmbH, founded in 2014 and headquartered in Heidelberg, Germany with a wholly-owned U.S. subsidiary (Molecular Health Inc.), develops AI-driven biomedical data intelligence software for pharmaceutical, biotechnology, and research laboratory customers. Its core technology platform, Dataome Technology, uses proprietary AI/ML text-mining combined with expert curation to structure and integrate molecular, biomedical, and drug-related data into a proprietary knowledgebase covering the human molecular landscape. On top of this platform the company offers two product lines: MH Guide / MH Guide CAS, variant annotation and reporting software for genetic and molecular tumor data (with sub-modules including MH Guide/BRCA for PARP inhibitor variant interpretation and MH Guide/Mendel for hereditary disease genes); and AI Pharma Solutions, a fee-for-service offering for indication finding, biomarker discovery, target identification, trial design and endpoint optimization, and drug safety prediction via the MH Effect and MH Predict technologies.

The company operates an enterprise field sales motion targeting pharma/biotech and research laboratories, with dedicated customer success teams in Germany and the U.S. and contact-based pricing (no published tiers). Distribution is augmented by strategic channel partnerships, notably a global multi-year agreement with Integrated DNA Technologies (IDT, May 2024) pairing MH Guide with IDT's Archer NGS assay platform, and a strategic collaboration with Axxam S.p.A. (June 2025) pairing Dataome insights with biological validation for drug target discovery. Molecular Health is privately held by its founders (CEO Dr. Friedrich von Bohlen und Halbach; CTO Dr. Stephan Brock) with no disclosed external funding rounds or parent company, operates under GDPR-compliant data practices, and maintains an active scientific publication record (18 articles spanning 2016-2026).

Molecular Health firmographics

Firmographics
Name
Molecular Health
Legal name
Molecular Health GmbH
Website
https://molecularhealth.com
Company type
Private
Founded year
2014
Operating status
Operating
Headcount range
101–250 employees
Short description
Molecular Health is a Heidelberg-based AI biomedical data intelligence company that operates the Dataome knowledge platform and MH Guide variant annotation software to serve pharmaceutical, biotech, and research laboratory customers with drug development and clinical genomics analytics.
Ownership category
akta.pro rank

Molecular Health industry classification

Industry
Product category
Clinical Genomics and Bioinformatics Software
NAICS
Software Publishers (5132), Research and Development in Biotechnology (except Nanobiotechnology) (541714)
akta.pro industry
PRIMARYHLAGAJAO
AI/ML Platforms for Drug Discovery & Experiment Optimization
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Life Science Software & Informatics (LIMS/ELN/Bioinformatics)
SECONDARYHLAAAIAI
Target Identification & Validation Platforms (omics-driven, chemoproteomics, genetic validation)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAAALAO
Digital & AI-Enabled Diagnostics (algorithmic interpretation, decision support tied to assays)

Keywords

  • Biomedical data analytics
  • Variant annotation software
  • AI drug discovery
  • Clinical genomics software
  • Biomedical knowledge platform

Where Molecular Health is headquartered

Location

Headquarters

HQ city
Heidelberg
HQ country
Germany
HQ region
Europe

Offices4 records

Markets served

Molecular Health business model

Business model
GTM type
B2B
Offering type
Software
Cost components
Technology or R&D, Personnel, Operations, Marketing or Sales, Others

Revenue model

  1. Software Solutions for Research: Software licensing and subscription services for variant annotation, reporting, and analysis tools used by research laboratories and pharmaceutical companies. Includes MH Guide CAS for genetic data annotation.
  2. AI Pharma Solutions Services: Fee-for-service analytical projects using Dataome Technology for indication finding, biomarker discovery, target identification, trial design, endpoint optimization, and safety prediction.
  3. Integrated Software Partnerships: Revenue through partnership arrangements that integrate Molecular Health's software with partner platforms (e.g., IDT's NGS workflow), extending distribution reach.

Go-to-market motion2 records

Distribution channels3 records

Marketing channels4 records

Molecular Health product offering

Product offering

Core offering

Molecular Health develops and sells AI-powered software that transforms biomedical and molecular data into actionable insights for drug development and clinical genomics. Its primary products are MH Guide (a variant annotation and clinical reporting software for genetic and tumor data) and the Dataome biomedical knowledge base, complemented by AI Pharma Solutions services that apply these capabilities to indication finding, biomarker discovery, target identification, trial design optimization, and drug safety prediction for pharmaceutical and research laboratory customers.

Product overview

Molecular Health offers a platform-plus-modules architecture centered on Dataome Technology and MH Guide. Dataome is the core AI-powered biomedical knowledge base that integrates and contextualizes molecular, biomedical, and drug-related data. MH Guide is the primary clinical software for annotating genetic variants with therapy associations and biomarkers. These are supplemented by specialized modules including MH Guide/BRCA for BRCA variant interpretation, MH Guide/Mendel for hereditary disease genes, MH Order Portal for case management, and MH VCF Adapter Suite and MH Connector for NGS workflow integration. The AI Pharma Solutions product line leverages Dataome for pharma/biotech clients requiring indication finding, biomarker identification, target identification, trial design optimization, and drug safety prediction via MH Effect technology.

Differentiator

Problem solved

Functional benefit

Brands

  • MH Guide CAS: Case Annotation Solution for annotating genetic and molecular tumor alteration data with published therapy associations, biomarkers, and recruiting clinical trials for research guidance.
  • Dataome
  • AI Pharma Solutions

Products and services

  • MH Guide / MH Guide CAS (Case Annotation Solution)

Quantifiable outcome

  • Provides tertiary analysis for NGS data, maximizing lab efficiency and streamlining genomics workflows

Companies that use Molecular Health

Customer profile

Named customers2 records

Segments2 records

Ideal customer profiles2 records

Molecular Health technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Integration2 records

AI capability6 records

Feature6 records

Molecular Health partnerships and signals

Strategic signal

Partnerships

Two partnerships are on record, tiered core.

  • Axxam S.p.A.coreStrategic or Co-development Partner · 4 June 2025Strategic collaboration pairing data-driven clinical-molecular insights with biological validation to identify relevant drug targets and confirm leads for biopharmaceutical companies. Combines Molecular Health's Dataome Technology with Axxam's integrated early discovery services capabilities.
  • Integrated DNA Technologies (IDT)coreChannel Partner/ Reseller/ Distributor · 15 May 2024Global multi-year agreement pairing IDT's Archer NGS research assay platform with Molecular Health's variant annotation and reporting software. Equips molecular researchers with tertiary analysis for NGS data, maximizing lab efficiency and streamlining genomics data workflows. Extends access to research customers through IDT's nationwide (U.S.) footprint and global presence. Collaboration enables high-quality, end-to-end integration plus deep understanding of sequencing data for cancer discoveries.

Scale indicators3 records

Recent moves6 records

Expansion highlights5 records

Molecular Health competitors and assessment

Company assessment

Direct peers

  • SOPHiA Genetics: SOPHiA Genetics provides AI-powered variant annotation and interpretation for clinical and research genomics. Both companies offer tertiary NGS analysis, biomarker annotation, and clinical trial matching for pharma/research customers, directly competing in variant interpretation.
  • Fabric Genomics: Fabric Genomics specializes in NGS variant interpretation and clinical decision support for genomic medicine. Directly comparable to Molecular Health's MH Guide and MH Guide CAS for variant annotation, reporting, and clinical research workflows.
  • Congenica: Congenica provides clinical genomics interpretation software for rare disease and hereditary cancer variants. Comparable use cases to Molecular Health's MH Guide/Mendel and MH Guide/BRCA modules for hereditary disease gene interpretation.
  • Golden Helix: Golden Helix offers variant annotation and clinical reporting software for NGS workflows. Competes in similar territory as Molecular Health's MH Guide CAS for research laboratories and clinical genomics reporting.
  • Schrödinger: Schrödinger provides a computational platform for drug discovery including target identification, molecular design, and predictive modeling. Comparable to Molecular Health's AI Pharma Solutions and Dataome Technology for pharma/biotech target identification and indication finding.
  • Recursion Pharmaceuticals: Recursion is an AI-driven drug discovery platform combining high-throughput biology with machine learning. Overlaps with Molecular Health's AI Pharma Solutions for target identification, indication finding, and predictive analytics in pharma/biotech.
  • Exscientia: Exscientia applies AI to drug design and target discovery with patient-derived data. Comparable to Molecular Health's predictive analytics capabilities for drug development, indication finding, and safety prediction.

Broad incumbents

  • QIAGEN: QIAGEN is a major life sciences tools and bioinformatics provider offering QIAseq and Ingenuity variant analysis tools. Broader portfolio than Molecular Health but significant overlap in NGS variant interpretation and clinical genomics workflows.
  • Tempus AI: Tempus AI is a data-driven precision medicine company offering AI-enabled diagnostics, biomarker discovery, and clinical trial matching. Broader portfolio but overlapping use cases in biomarker identification, trial matching, and pharma data services.
  • Illumina: Illumina is the dominant NGS platform provider with adjacent bioinformatics offerings through BaseSpace and various partnerships. As a broader incumbent, Illumina's ecosystem competes with Molecular Health's IDT partnership for NGS workflow ownership.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks5 records

Key highlights6 records

Customer concentration

Molecular Health social profiles

Digital presence

Molecular Health compliance and trust

Trust signal

Compliance1 record

Molecular Health financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Molecular Health leadership team

Management profile

Number of profiles

Profiles4 records

Molecular Health subsidiaries and ownership

Company hierarchy

Subsidiaries1 record

Molecular Health funding detail

Funding detail

Funding overview

Funding rounds1 record

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Molecular Health M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Molecular Health

What does Molecular Health do?

Molecular Health develops and sells AI-powered software that transforms biomedical and molecular data into actionable insights for drug development and clinical genomics. Its primary products are MH Guide (a variant annotation and clinical reporting software for genetic and tumor data) and the Dataome biomedical knowledge base, complemented by AI Pharma Solutions services that apply these capabilities to indication finding, biomarker discovery, target identification, trial design optimization, and drug safety prediction for pharmaceutical and research laboratory customers.

Is Molecular Health a public or private company?

Molecular Health is a private company. It is classified as founder individual operated bootstrapped and is currently operating.

When was Molecular Health founded?

Molecular Health was founded in 2014. It employs 101 to 250 people.

Where is Molecular Health based?

Molecular Health is headquartered in Heidelberg, Germany, in the Europe region.

How does Molecular Health make money?

Three revenue lines are on record. Software Solutions for Research is the primary driver. The others are AI Pharma Solutions Services and integrated Software Partnerships.

Who are Molecular Health's main competitors?

Direct peers on record are SOPHiA Genetics, Fabric Genomics, Congenica, Golden Helix, Schrödinger, Recursion Pharmaceuticals and Exscientia. Broad incumbents are QIAGEN, Tempus AI and Illumina.

Does Molecular Health have an API?

No public API is recorded for Molecular Health.

What industry is Molecular Health in?

Molecular Health's product category is Clinical Genomics and Bioinformatics Software. Its primary akta.pro industry code is HLAGAJAO, AI/ML Platforms for Drug Discovery & Experiment Optimization, with a secondary code of HLAAAIAI, Target Identification & Validation Platforms (omics-driven, chemoproteomics, genetic validation). Its NAICS code is 5132.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
News-MedicalAI-powered analytics and experimental validationIn an interview published on July 23, 2026, executives from Molecular Health and Axxam discussed how their companies combine AI-powered analytics with experimental validation to improve drug target identification in drug discovery. The discussion highlighted Molecular Health's multimodal data environment and knowledge graph approach for target prioritization, alongside Axxam's experimental validation strategy using genetic perturbation, phenotypic profiling, and functional assays across multiple disease areas. The companies emphasized that integrating computational predictions with biological validation creates a continuous feedback loop that strengthens decision-making throughout the discovery process.Labiotech.euNew names, new narratives: Why biotechs decide to rebrandGalapagos rebranded as Lakefront Biotherapeutics after winding down its cell therapy business, incurring €150-200 million in restructuring costs. Hoth Therapeutics pivoted to space and AI, becoming Rocket One, with shares jumping nearly 40%. Molecular Health's Dataome business launched as Lucera, focusing on decision intelligence.HLTHLucera Launches Following Molecular Health Technology Acquisition to Advance AI-Driven Drug Development IntelligenceLucera GmbH has launched as a new TechBio company in Heidelberg, Germany, after a consortium of institutional and private investors acquired the pharmaceutical technology business of Molecular Health GmbH. The company's core offering is Dataome®, a biomedical knowledge base and Knowledge Graph platform developed over more than 15 years that integrates fragmented biomedical data to support drug development decisions. Lucera begins operations with 25 employees transferred from Molecular Health and plans to serve pharmaceutical, biotechnology, and investment sector clients through consulting services and software offerings.TradingViewLaunch of TechBio firm, Lucera, brings decision intelligence to drug development, making it more predictable, more evidence-grounded, and more efficientLucera GmbH, a newly launched TechBio company, has been established through the acquisition of the pharmaceutical technology business of Molecular Health GmbH by a consortium of institutional and private investors. The company leverages its proprietary Dataome® technology — a semantically integrated biomedical knowledge base developed over 15 years — to provide decision intelligence in drug development, helping pharma and biotech clients reduce R&D costs and bring products to patients faster. Lucera is headquartered in Heidelberg, Germany, employs 25 staff drawn from Molecular Health, and serves an international client base including pharmaceutical firms, biotech companies, and venture capital investors.European BiotechnologyA fresh start for Molecular Health: technology core becomes start-up LuceraMolecular Health's pharma technology business is being relaunched as Lucera GmbH, with an investor consortium acquiring it. The company, led by Friedrich von Bohlen and Stephan Brock, will carry forward its Dataome knowledge platform, serving over 20 clients. Lucera aims to develop data-driven decision support for drug development in a leaner, market-focused way.openPR.comMolecular Tumor Board Solutions Market Overview, Key Trends, and Major Player AnalysisThe molecular tumor board solutions market is projected to reach $2.87 billion by 2030, growing at a compound annual growth rate of 13.4%, driven by rising investments in personalized oncology, cloud-based healthcare platforms, and AI-driven analytics in oncology. In September 2024, Labcorp Holdings Inc. acquired BioReference Health LLC for $237.5 million to expand its laboratory services and improve clinical testing accessibility for patients and healthcare providers. The market analysis highlights trends including AI-assisted variant interpretation, multimodal genomic data integration, and cloud-based collaborative platforms as key drivers shaping the industry.GlobeNewswireMolecular Tumor Board Solutions Market Outlook 2026-2030 & 2035 with Competitor Market Share DataResearchAndMarkets.com has released a market report projecting the molecular tumor board solutions market to grow from $1.53 billion in 2025 to $1.74 billion in 2026 and $2.87 billion by 2030, driven by precision oncology expansion and genomic sequencing adoption. Key corporate activities include Guardant Health Inc.'s launch of the Guardant360 Tissue profiling test in April 2025 and Labcorp Holdings Inc.'s $237.5 million acquisition of BioReference Health LLC in September 2024. The report identifies AI-assisted variant interpretation and cloud-based platforms as emerging trends, with North America holding dominant market share in 2025 while Asia-Pacific is projected as the fastest-growing region.YahooMolecular Health and Axxam enter into a strategic partnership to bolster the discovery of innovative targets in drug developmentAxxam S.p.A. and Molecular Health GmbH announced a strategic partnership to accelerate drug target discovery by integrating Molecular Health's AI platform Dataome with Axxam's DiscoveryMAXX. The collaboration combines computational predictions with biological validation using iPSC-based models to identify novel therapeutic targets.Business Wire BlogIntegrated DNA Technologies and Molecular Health Ink Commercial PartnershipIntegrated DNA Technologies and Molecular Health signed a global multi-year agreement to integrate their next-generation sequencing capabilities. The partnership combines IDT's Archer NGS platform with Molecular Health's variant annotation software to streamline cancer research workflows. It aims to accelerate cancer discoveries through improved genomic data analysis.